Skip to main content

Discovery and Design of Retinoic Acid Receptor and Retinoid X Receptor Class- and Subtype-Selective Synthetic Analogs of All-trans-retinoic Acid and 9-cis-Retinoic Acid

Buy Article:

$55.00 plus tax (Refund Policy)

This review presents a historical overview of the discoveries of retinoic acid receptor (RAR) and retinoid X receptor (RXR) class- and subtype-selective synthetic retinoids. These synthetic retinoids are conformationally restricted by having aromatic rings in place of the tetraene bond systems of all-trans- and 9-cis- retinoic acids. Events leading to the design and synthesis of such retinoid transcriptional agonists as RAR subtype β,γ-selective 6-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-naph-thalenecarboxyl ic acid (TTNN), the RARγ-selective Z-oxime of 6-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenylcarbonyl)-2-naphthalenec arboxylic acid (SR11254), RAR-selective 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl) benzoic acid (TTAB), RXR-selective 4-[1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-cyclopropyl] benzoic acid (SR11246), RXR-selective 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-methylpropenyl] benzoic acid (SR11345), and RARγ-selective retinoid transcriptional antagonist 2-(6-carboxy-2- naphthalenyl)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,3-dith iolane (SR11253) are described.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Retinoic Acid Receptor; carbonyl group; naphthalenecarboxylic acid; retinoid X receptor (RXR); tetrahydronaphthalene ring

Document Type: Review Article

Publication date: 2002-03-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more